Study to assess the ability of healthy subjects to build anitbodies to tetanus and pneumococcal vaccines after receiving a single intravenous dose of Abatacept, a drug which is being developed for the treatment of Rheumatoid Arthritis and which can affect the immune system.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
80
0 mg + vaccines, Single dose, 28 days.
Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.
Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.
Qutintiles Phase I Services
Lenexa, Kansas, United States
Parexel International Corp
Baltimore, Maryland, United States
PPD Development
Austin, Texas, United States
Assess effect of single 750mg dose of Abatacept on antibody response to tetanus toxioid and 23-valent pneumococcal vaccines.
Assess safety and tolerability of Abatacept given in conjunction with tetanus toxoid and 23-valent pneumococcal vaccines.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.